Simeon George, M.D.

Simeon is CEO and Managing Partner of SR One, with overall responsibility for the fund and is Chair of the Investment Committee. Simeon joined SR One in 2007 and established its San Francisco office in 2010. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB), Turning Point Therapeutics (TPTX), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded.

Simeon has a BA from the Johns Hopkins University and an MD/MBA from the University of Pennsylvania School of Medicine/The Wharton School.